🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 1 día
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 09/06/2009 | 31,01 | 31,05 | 30,37 | 30,55 | -0,81% | 2,19% | 1.033.100 |
| 08/06/2009 | 30,45 | 31,06 | 30,19 | 30,80 | +0,06% | 2,86% | 1.427.300 |
| 05/06/2009 | 30,64 | 30,85 | 30,15 | 30,78 | +1,25% | 2,28% | 1.098.200 |
| 04/06/2009 | 31,68 | 31,78 | 30,29 | 30,40 | -3,55% | 4,70% | 1.608.100 |
| 03/06/2009 | 30,70 | 31,64 | 30,41 | 31,52 | +2,24% | 4,01% | 1.801.300 |
| 02/06/2009 | 29,14 | 31,00 | 29,03 | 30,83 | +2,63% | 6,76% | 1.947.900 |
| 01/06/2009 | 30,00 | 30,20 | 29,59 | 30,04 | +0,91% | 2,03% | 1.710.400 |
| 29/05/2009 | 28,81 | 29,82 | 28,18 | 29,77 | +3,44% | 5,69% | 2.457.900 |
| 28/05/2009 | 29,21 | 29,35 | 28,57 | 28,78 | -1,30% | 2,67% | 1.150.100 |
| 27/05/2009 | 29,59 | 29,93 | 29,05 | 29,16 | -1,55% | 2,97% | 2.532.600 |
| 26/05/2009 | 28,51 | 29,81 | 28,15 | 29,62 | +1,96% | 5,82% | 1.514.200 |
| 22/05/2009 | 28,87 | 29,14 | 28,61 | 29,05 | +0,69% | 1,84% | 1.156.100 |
| 21/05/2009 | 29,36 | 29,44 | 28,56 | 28,85 | -2,10% | 3,00% | 1.912.500 |
| 20/05/2009 | 29,44 | 29,55 | 29,03 | 29,47 | +0,44% | 1,77% | 2.285.200 |
| 19/05/2009 | 29,00 | 29,47 | 28,70 | 29,34 | +0,82% | 2,66% | 1.227.700 |
| 18/05/2009 | 28,60 | 29,14 | 28,07 | 29,10 | +1,96% | 3,74% | 1.518.700 |
| 15/05/2009 | 28,73 | 28,96 | 28,12 | 28,54 | -1,45% | 2,92% | 1.203.500 |
| 14/05/2009 | 29,09 | 29,80 | 28,55 | 28,96 | -0,07% | 4,30% | 1.875.900 |
| 13/05/2009 | 29,74 | 30,12 | 28,73 | 28,98 | -3,17% | 4,67% | 1.592.900 |
| 12/05/2009 | 31,00 | 31,05 | 29,71 | 29,93 | -2,44% | 4,32% | 1.398.200 |
| 11/05/2009 | 30,02 | 30,95 | 29,63 | 30,68 | +0,76% | 4,40% | 2.069.100 |
| 08/05/2009 | 28,89 | 30,65 | 28,89 | 30,45 | +4,68% | 6,09% | 2.304.000 |
| 07/05/2009 | 28,71 | 29,26 | 28,57 | 29,09 | +1,04% | 2,40% | 2.064.600 |
| 06/05/2009 | 30,22 | 30,32 | 28,67 | 28,79 | -4,67% | 5,46% | 2.025.300 |
| 05/05/2009 | 30,60 | 30,60 | 29,63 | 30,20 | -1,02% | 3,17% | 1.430.300 |
| 04/05/2009 | 30,50 | 31,00 | 29,78 | 30,51 | +0,83% | 4,00% | 1.563.600 |
| 01/05/2009 | 30,83 | 30,86 | 29,85 | 30,26 | -1,82% | 3,28% | 1.689.700 |
| 30/04/2009 | 32,46 | 32,80 | 30,45 | 30,82 | -3,99% | 7,24% | 3.176.000 |
| 29/04/2009 | 32,26 | 32,35 | 31,26 | 32,10 | +0,69% | 3,38% | 2.572.700 |
| 28/04/2009 | 28,85 | 32,20 | 28,58 | 31,88 | +9,86% | 12,55% | 6.068.300 |